Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
112 participants
OBSERVATIONAL
2020-04-01
2021-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19
NCT04364893
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19
NCT05398731
The COVID-RASi Trial (COVID-19)
NCT04591210
ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19
NCT04318418
Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19
NCT04493359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
COVID-19 is confirmed by a PCR test, the disease follow-up is divided into 2 periods: up to 12 weeks and up to 24 weeks.
Primary Outcome Measure: BP was known one week before COVID-19 and is tested during the disease onset on weeks 2, 4, 12, 24. Secondary Outcome Measures are clinical features. Subanalysis in patients with CKD is additionally performed for those who have CKD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ARB group
Hypertensive patients with COVID-19 who received ARBs
Angiotensin Receptor Blockers
routine drug intake
ACEi group
Hypertensive patients with COVID-19 who received ACEis
Angiotensin converting enzyme inhibitor
routine drug intake
DRi group
Hypertensive patients with COVID-19 who received direct renin inhibitor (DRis)
Direct renin inhibitor
routine drug intake
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Angiotensin converting enzyme inhibitor
routine drug intake
Angiotensin Receptor Blockers
routine drug intake
Direct renin inhibitor
routine drug intake
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical Practice Prof D. Ivanov
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iryna Zavalna, MD
Role: STUDY_CHAIR
Nephrology clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Practice Prof D.Ivanov
Kiev, Please Select, Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COVID20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.